Equities analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to announce earnings of ($1.07) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Five Prime Therapeutics’ earnings. The highest EPS estimate is ($0.81) and the lowest is ($1.50). Five Prime Therapeutics posted earnings of ($0.63) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 69.8%. The business is scheduled to announce its next quarterly earnings report on Tuesday, May 14th.
On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.99) per share for the current fiscal year, with EPS estimates ranging from ($5.96) to ($3.35). For the next fiscal year, analysts forecast that the business will report earnings of ($2.95) per share, with EPS estimates ranging from ($3.67) to ($2.23). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.12) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.20. Five Prime Therapeutics had a negative net margin of 281.64% and a negative return on equity of 44.55%.
Several brokerages have recently issued reports on FPRX. ValuEngine raised shares of Five Prime Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, March 20th. BidaskClub raised shares of Five Prime Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Cowen restated a “buy” rating on shares of Five Prime Therapeutics in a report on Wednesday, February 27th. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Monday, January 21st. Finally, Wedbush upgraded shares of Five Prime Therapeutics from a “neutral” rating to an “outperform” rating and set a $16.00 price target on the stock in a research report on Thursday, January 17th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $24.29.
Shares of NASDAQ:FPRX traded up $0.21 during trading hours on Friday, hitting $13.58. 205,562 shares of the company’s stock traded hands, compared to its average volume of 319,832. Five Prime Therapeutics has a 52 week low of $7.84 and a 52 week high of $19.70. The firm has a market cap of $481.95 million, a price-to-earnings ratio of -3.29 and a beta of 3.18.
Hedge funds have recently bought and sold shares of the business. Great Point Partners LLC boosted its holdings in shares of Five Prime Therapeutics by 45.6% in the fourth quarter. Great Point Partners LLC now owns 2,398,409 shares of the biotechnology company’s stock worth $22,305,000 after buying an additional 750,656 shares during the period. Sofinnova Investments Inc. purchased a new position in shares of Five Prime Therapeutics in the fourth quarter worth approximately $2,933,000. DekaBank Deutsche Girozentrale increased its position in shares of Five Prime Therapeutics by 1,901.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 284,200 shares of the biotechnology company’s stock worth $4,019,000 after acquiring an additional 270,000 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Five Prime Therapeutics by 18.8% during the third quarter. Dimensional Fund Advisors LP now owns 1,413,177 shares of the biotechnology company’s stock valued at $19,671,000 after acquiring an additional 223,523 shares during the period. Finally, Hudson Bay Capital Management LP raised its holdings in shares of Five Prime Therapeutics by 70.7% during the fourth quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $3,255,000 after acquiring an additional 145,000 shares during the period. 86.62% of the stock is owned by institutional investors.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: Cryptocurrencies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.